Statins Help, Low Cholesterol Hurts Survival in Acute HF

November 29, 2006

November 29, 2006 (Chicago, IL) - To borrow from Winston Churchill, it's a "cholesterol paradox" wrapped in a mystery inside an enigma, counterintuitive at several levels but consistent with a good deal of epidemiologic and mechanistic evidence. A large observational study of patients with acute heart failure has suggested that short-term mortality goes up as admission serum total cholesterol (TC) levels go down, yet such patients appear to live longer if they are on statins [1].

Chronic heart failure has previously been associated with a so-called "reverse epidemiology," in which, for example, body-mass index, blood pressure, and serum cholesterol are inversely correlated with mortality [2,3], but it is unclear whether they are mediators or simply markers of risk. The current analysis, based on a European multicenter registry of patients hospitalized with HF, suggests the inverse TC-mortality relationship is independent and points to effects other than lipid modification as central to any clinical benefit HF patients may gain from the drugs, according to the investigators.

Twelve-week mortality for the study's >5000 patients admitted for acute HF was about 12.5%, but the adjusted mortality odds ratio was reduced by a significant 40% for those with serum TC >193 mg/dL (5 mmol/L) compared with lower levels and for those on vs not on lipid-lowering therapy, which was presumed to consist primarily of statins. The reductions were independent of other significant outcome predictors that included creatinine, LV systolic function, and treatment with beta blockers or ACE inhibitors, reported Dr Periaswamy Velavan (University of Hull, Kingston-upon-Hull, UK) recently at the American Heart Association 2006 Scientific Sessions.

Mean baseline serum total cholesterol levels, survivors vs nonsurvivors at 12 weeks

Population

Survivors, n=5123

Nonsurvivors, n=606

Combined

Lipid-lowering therapy, n=1506 (mg/dL)

202

198

202

No lipid-lowering therapy, n=4223 (mg/dL)

194

178

192*

Combined (mg/dL)

196

180

194

*p<0.001 vs all survivors and nonsurvivors on lipid-lowering therapy. †p<0.001 vs survivors.

The apparent paradox of an inverse TC-mortality relationship became clearer after analysis by TC quintiles. Those with the poorest prognosis, who had TC levels below 151 mg/dL, accounted for almost a third of the deaths. But the curve for TC vs mortality was U-shaped for the 26% of the cohort on lipid-lowering therapy. Among them, those with TC levels in the middle quintiles fared the best and those in the first and fifth quintiles did the worst. Lipid-lowering therapy was associated with a greatly reduced 12-week mortality regardless of admission TC levels.

Mortality by serum total cholesterol quintile, all heart-failure patients and those on lipid-lowering therapy

End point

<151 mg/dL

151-179 mg/dL

180-205 mg/dL

206-235 mg/dL

>235 mg/dL

Total population

         
Mortality (% within quintile)

16.6

10.8

8.9

9.0

7.4

Proportion of deaths (%)

32.7

19.6

17.4

16.6

13.7

Patients on lipid-lowering therapy

         
Mortality (% within quintile)

5.8

5.2

4.0

3.1

5.2

Proportion of deaths (%)

22.5

19.7

16.9

11.3

29.6

The findings argue against lipid lowering per se as the mechanism of statin benefit in the HF population, Velavan told heartwire. The drugs' other well-recognized benefits include anti-inflammatory effects and improvements in endothelial function, and they may also have antiarrhythmic and angiogenic properties, he observed. But it's unknown whether lowering initially "normal" or low TC levels with statins will improve outcomes in the setting of HF. The current limited analysis suggests that may be the case, but "only randomized trials can answer that question."

Velavan explained that low TC levels in HF may reflect increased metabolic stress due to endotoxins or oxidative or inflammatory processes. Patients with the lowest TC levels, he said, "are possibly the sickest patients, with the highest levels of inflammation. We believe that it is possibly the severe inflammatory response associated with the advanced heart-failure patient that causes the low cholesterol." In support of that view, he said, other conditions characterized by a severe inflammatory response and high mortality, such as trauma or septic shock, are known to be associated with low cholesterol levels.

  1. Velavan P. Prognostic implications of low cholesterol and statin therapy in heart failure. "The cholesterol paradox." American Heart Association 2006 Scientific Sessions; November 12, 2006; Chicago, IL. Abstract 342.

  2. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43:1439-1444.

  3. Horwich TB, Hamilton MA, MacLellan WR, Fonarow GC. Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002; 8:216-224.

The complete contents of Heartwire , a professional news service of WebMD, can be found at www.theheart.org, a Web site for cardiovascular healthcare professionals.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....